Good evening :)
Switch to
Place Order

Neuland Laboratories Ltd

NEULANDLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,237 cr, stock is ranked 753
High RiskStock is 3.26x as volatile as Nifty
1,771.901.58% (+27.60)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,237 cr, stock is ranked 753
High RiskStock is 3.26x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
35.072.660.29%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.694.330.89%

Forecast & RatingsDetailed Forecast 

67%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Neuland Laboratories Limited is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The Company operates through manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services. The Company’s capabilities include FBRM, research and development, peptide laboratory, poly block reactors, laboratory reactors, heating and cooling systems, hazardous and wet laboratory, PID Laboratory Unit-III, PID Laboratory B-S Unit-I, and other lab equipment. The Company has 3 manufacturing facilities and one R&D facility in Hyderabad.

Investor PresentationView older 

May 10, 2022

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+670.32+766.60+953.01+953.16+16.44+16.21+80.63+63.82
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 7.78%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

General updates 
Announced OnNov 23, 2022

Board approved the transfer of Company¬タルs property situated at Nanakramguda, Hyderabad by way of perpetual lease, subject to receipt of requisite approvals | Download

Board approved the transfer of Company¬タルs property situated at Nanakramguda, Hyderabad by way of perpetual lease, subject to receipt of requisite approvals | Download

Appointment 
Announced OnNov 23, 2022

Appointment of Mr. Abhijit Majumdar, as the Chief Financial Officer (CFO) and KMP of the Company. | Download

Appointment of Mr. Abhijit Majumdar, as the Chief Financial Officer (CFO) and KMP of the Company. | Download

Cash Dividend 
Ex. DateJul 14, 2022

Final • Div/Share: ₹ 5

See all events